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Mycoplasma hominis is a fastidious micro-organism causing genital and extragenital infections. We developed a specific real-time
PCR that exhibits high sensitivity and low intrarun and interrun variabilities. When applied to clinical samples, this quantitative
PCR allowed to confirm the role of M. hominis in three patients with severe extragenital infections.
Mycoplasma hominis are fastidious bacteria, which are not
detected on routinely used axenic media [1]. Lack of a
cell wall makes these organisms naturally resistant to β-
lactam antibiotics and not detectable by Gram staining. M.
hominis is a recognized agent of genital infections in adults
as well as of neonatal infections [2, 3]. Furthermore, it
has been reported as the etiologic agent of various serious
extra-genital infections such as brain abscess, pneumonia,
mediastinitis, pericarditis, endocarditis, osteitis, arthritis,
wound infections, peritonitis, and pyelonephritis both in
immunosuppressed and in immunocompetent individuals
[4–11]. Since most commonly used antibiotics in clinical
practice are not active against M. hominis, the diagnosis of
infections due to this fastidious bacterium is a crucial issue,
especially for extra-genital cases.
In this context, we developed a real-time PCR assay for
the detection of M. hominis. Then, this new PCR was applied
to clinical samples obtained from patients suﬀering from
extra-genital M. hominis infections.
A forward primer MhF (5-TTTGGTCAAGTCCTGC-
AACGA-3
′
, position 2472–2493 of GenBank sequence
AF443616), a reverse primer MhR (5
′
-CCCCACCTTCC-
TCCCAGTTA-3
′
, position 2553–2572 of AF443616),
which amplifies a 101 bp part of the 16S rRNA-encoding
gene, and a minor-groove binder probe labeled with 5
′
VIC (TACTAACATTAAGTTGAGGACTCTA, position 2513–
2537 of AF443616) were selected using the Primer Express
software (Applied Biosystems, Darmstadt, Germany). The
reactions were performed in a final volume of 20 μl, including
0.2 μM of each primer, 0.2. μM of probe, 10 μl 2× TaqMan
Universal Master Mix (Applied Biosystems), and 5 μl of
DNA sample. The cycling conditions were 2min at 50◦C
and 10min at 95◦C, followed by 45 cycles of 15 s at 95◦C
and 1min at 60◦C. An ABI Prism 7900 instrument (Applied
Biosystems) was used for the amplification and detection
of the PCR products. The specificity of the real-time PCR
was high, being increased by the use of a TaqMan probe.
No cross-amplification was observed when 5 ng of genomic
DNA of humans, fungus (Candida albicans ATCC 10231),
and 15 diﬀerent bacterial strains were tested (Mycoplasma
pneumoniae, Ureaplasma parvum, Ureaplasma urealyticum,
Gardnerella vaginalis, Lactobacillus sp., Chlamydia tra-
chomatis, Chlamydophila pneumoniae, Enterococcus faecalis,
Escherichia coli, Haemophilus influenzae, Klebsiella pneumo-
niae, Pseudomonas aeruginosa, Staphylococcus saprophyticus,
Streptococcus pyogenes, and Streptococcus agalactiae). A
plasmid containing the target gene was constructed to
perform the quantification step, as described previously [12].
Duplicates of 10-fold serial dilutions of the plasmid were
run in ten independent experiments in order to analyze
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Figure 1: Intra and interrun reproducibility of the real-time PCR assessed on duplicate of plasmid positive controls performed at 10-fold
dilutions from 1000 to 10 plasmid copies/5 μL during 10 successive runs. (a) Plots of the cycle threshold (Ct) of first and second duplicates,
showing intrarun variability of the real-time PCR between duplicates of positive plasmid controls; 95% confidence interval is shown by the
dashed lines. (b) Bland-Altman graph showing the ratio of Ct of both duplicates according to the mean of the Ct of duplicates. (c) Plots of
the mean of duplicate of plasmid positive controls according to each successive run, showing the low interrun variability of the real-time
PCR. Standard deviations show the intrarun reproducibility of the PCR.
the sensitivity and the reproducibility of the PCR results.
As shown in Figure 1(a), the intrarun reproducibility was
excellent. As expected, intrarun variability was slightly higher
at very low concentration of target DNA (Figure 1(b)). The
interrun variability was low, except at a low concentration
of 10 plasmid copies per 5 μl (Figure 1(c)). Thus, the mean
Ct values +/−1 standard deviation were of 29.64 +/− 0.38
(1.28%), 32.69 +/−0.36 (1.10%), and 36.43 +/−0.49 (1.34%)
for 1000, 100, and 10 DNA copies per 5 μl. The analytical
sensitivity of the real-time PCR was 10 copies of plasmid
control DNA per reaction mixture, that is, similar to the
light-cycler PCR already reported by Baczynska et al. [14].
This sensitivity is about 10-fold better than the 16SrRNA
broad-range PCR developed by Bosshard et al. [15]. When
testing genomic DNA obtained by growing M. hominis in
culture, we again obtained an excellent sensitivity which was
of about 1000 bacteria/ml. When serially diluting a clinical
sample (inguinal abscess of patient 1), the eubacterial PCR
was slightly positive when the real-time specific Mycoplasma
PCR was positive with a Ct of 33.4 (45 copies in 5 μl of DNA)
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Table 1: Characteristics of three patients with Mycoplasma hominis extra-genital infections, including clinical presentation and results of the
real-time PCR.
Patient
no.
Age Sex
Clinical
infection
Underlying
conditions
Other
etiology
Clinical specimen
M. hominis qPCR
results in copies/mL
Other positive
diagnostic tests
1 54 Female
Inguinal
lymphadenitis
with abscess
formation
Neutropenia,
HIV
None
Abscess fluida 16,175,000
Specific culturec and
broad-spectrum
PCR
Cervix swab 4,400
Vaginal swab 130
Urine 82
2 15 Female
Pneumonia and
pericarditis
None None
Abscess fluida 98,500,000
Specific culturec and
broad-spectrum
PCR
Pleural fluid 380,000
Pericardiac fluid 85
Sputumb 6
Pleural fluidb 0
3 56 Male Mediastinitis
Type A aortic
dissection
None
Mediastinal fluida 7,000
Blood agar dMediastinal swab 460
Blood 5
a First samples documenting the infection;
b Samples taken a few days after treatment start;
cCulture media: Mycoplasma IST, bioMe´rieux, France;
d Conventional culture positive on blood agar plate followed by sequencing for identification [13].
whereas eubacterial PCR was negative when the real-time
specific Mycoplasma PCR was positive with a Ct of 36.3 (6.5
copies in 5 μl of DNA).
Since growing evidence supports the role of M. hominis
as an emerging agent of extra-genital infections, the real-
time PCR was tested in 34 clinical samples taken from
15 patients suﬀering from various extra-genital infections.
These samples included physiologically sterile sites such as
pleural fluid, percardial fluid, cerebrospinal fluid, and cardiac
valve (n = 19) and from samples potentially contaminated
with oropharyngeal flora (n = 15), that is, mainly respiratory
tract samples (n = 8). DNA was extracted from 200 μl of
samples using theMagNAPureLC automated system (Roche)
and the MagnaPureLC DNA isolation kit 1 (Roche). DNA
was eluted in a final volume of 100 μl of the elution buﬀer
provided in the kit. A negative extraction control (DNA free
water extracted in parallel of the specimen) was tested for
each extraction run. Each sample was amplified in duplicate.
Inhibition control (specimen spiked with 1 μl containing
200 plasmid copies) and negative PCR mixture control were
systematically tested. All samples were investigated because
of clinical suspicion except two, for which the presence of
M. hominis DNA was already detected by a broad spectrum
16SrRNA PCR directly performed on the specimens [16].
Both were confirmed positive by the new PCR with very high
bacterial load (Table 1). DNA of M. hominis was also found
in samples of 1 out of the 13 remaining patients.
For all 3 positive patients, DNA of M. hominis was
detected in ≥3 specimens (Table 1). Moreover, for each of
these 3 patients, at least one of the positive molecular results
was further confirmed by culture with a commercial media
(Mycoplasma IST, bioMe´rieux, France) or on blood agar
(thin layer of bacteria and sequencing for identification)
[13]. Due to the high level of conservation of the 16S rRNA,
our real-time PCR is likely amplifying any member of the
M. hominis group that includes M. salivarium, M. orale,
and M. arginii. All cases presented in this paper were M.
hominis sensu stricto as confirmed by sequencing 16S rRNA
encoding gene. The clinical presentation of these three cases
is summarized in Table 1.
In conclusion, we developed a new PCR that exhibited
high sensitivity and that allowed us to diagnose or confirm
three extra-genital cases of M. hominis infections, which
may remain undetected due to the fastidious growth of
this bacterium. Recently, Masalma et al., using a cloning
and/or pyrosequencing sequencing approach, also identified
two extragenital M. hominis cerebral infections [4]. The
advantage of their strategy is the broad spectrum of the
approach that is not limited to Mycoplasma whereas the
advantages of our real-time PCR are simplicity, rapidity, and
lower risk of contamination.
This new real-time PCR represents an eﬃcient tool
for the diagnosis of M. hominis infections that may con-
tribute to better defining of the prevalence and pathogenic-
ity of M. hominis. Moreover, it could help to improve
clinical outcomes of severe extra-genital infections in
patients not responding to commonly used beta-lactam
antibiotics.
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